



500

JC14 Rec'd PCT/PT 17 MAY 2002

PCT

10/089394

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

12 pages +
52 references

Application Number 10/089,394

Filing Date March 29, 2002

First Named Inventor Halfeng CHEN

Group Art Unit To Be Assigned

Examiner Name To Be Assigned

Attorney Docket No. 226272007801

ENCLOSURES (check all that apply)

- | | | |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | 1. Form PTO-1449 + copy - 8 pages |
| <input checked="" type="checkbox"/> Information Disclosure Statement - 3 pages | <input type="checkbox"/> Request for Refund | 2. Fifty-two (52) references |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | 3. Return receipt postcard |
| <input type="checkbox"/> Response to Missing Parts/
Incomplete Application | | |
| <input type="checkbox"/> Response to Missing Parts
under 37 CFR 1.52 or 1.53 | | |

Remarks

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018
Signature	Debra J. Glaister (Registration No. 33,888)
Date	May 14, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 14, 2002.

Laura Shires

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT
Docket No. 226272007801

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on May 14, 2002.

Laura Shires
Laura Shires

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Haifeng CHEN and Gary KURTZMAN

Serial No.: 10/089,394

Filing Date: March 29, 2002

For: PRODUCTION OF RECOMBINANT
AAV USING ADENOVIRUS
COMPRISING AAV REP/CAP GENES

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for

any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 226272007801. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Dated: May 14, 2002

Respectfully submitted,

By: 

Debra J. Glaister
Registration No. 33,888

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5725
Facsimile: (650) 494-0792



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 226272007801

Application Number 10/089,394

Applicant

Haifeng CHEN and Gary KURTZMAN

Filing Date March 29, 2002

Group Art Unit To Be Assigned

Mailing Date May 14, 2002

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	10/11/1994	5,354,678	Lebkowski et al.			
	2.	08/19/1997	5,658,776	Flotte et al.			
	3.	08/19/1997	5,658,785	Johnson			
	4.	05/19/1998	5,753,500	Shenk et al.			
	5.	07/14/1998	5,780,280	Lebkowski et al.			
	6.	11/17/1998	5,837,484	Trempe et al.			
	7.	01/05/1999	5,856,152	Wilson et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	8.	03/09/1995	WO 95/06743 A2, A3	WIPO			
	9.	05/09/1996	WO 96/13598 A2, A3	WIPO			
	10.	01/03/1997	WO 97/00326 A1	WIPO			
	11.	02/20/1997	WO 97/06272 A2, A3	WIPO			
	12.	02/27/1997	WO 97/06826 A1	WIPO			
	13.	12/31/1997	WO 97/49824 A1	WIPO			
	14.	02/19/1998	WO 98/06864 A2, A3	WIPO			
	15.	06/25/1998	WO 98/27204 A2, A3	WIPO			
	16.	10/22/1998	WO 98/46728 A1	WIPO			
	17.	04/01/1999	WO 99/15685 A1	WIPO			


OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 226272007801

Application Number 10/089,394

Applicant

Haifeng CHEN and Gary KURTZMAN

Filing Date March 29, 2002

Group Art Unit To Be Assigned


Mailing Date May 14, 2002

Examiner Initials	Ref. No.	Title
	18.	Anderson, J. K. et al. "Herpesvirus-Mediated Gene Delivery into the Rat Brain: Specificity and Efficiency of the Neuron-Specific Enolase Promoter," <i>Cell. and Mol. Neurobiol.</i> 13(5):503-515.
	19.	Arbuthnot, P. B. et al. (August 1996). "In Vitro and In Vivo Hepatoma Cell-Specific Expression of a Gene Transferred with an Adenoviral Vector," <i>Hum. Gene Ther.</i> 7:1503-1514.
	20.	Berns, K. I. and Bohenzky, R. A. (1987). "Adeno-Associated Viruses: An Update," <i>Advances in Virus Research</i> 32:243-307.
	21.	Boshart, M. et al. (June 1985). "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," <i>Cell</i> 41:521-530.
	22.	Carter, B. J. (1990). "The Growth Cycle of Adeno-Associated Virus" Chapter 10 In <u>CRC Handbook of Parvoviruses</u> . P. Tijsser ed., CRC Press Inc. 1:155-168.
	23.	Chen, J. et al. (1996). "Expression of Rat Bone Sialoprotein Promoter in Transgenic Mice," <i>J. of Bone and Mineral Research</i> , 11(5):654-664.
	24.	Fisher, K. J. et al. (January 1996). "Transduction with Recombinant Adeno-Associated Virus for Gene Therapy is Limited by Leading-Strand Synthesis," <i>J. Virol.</i> 70(1):520-532.
	25.	Fisher, K. J. (November 1996). "A Novel Adenovirus-Adeno-Associated Virus Hybrid Vector that Displays Efficient Rescue and Delivery of the AAV Genome," <i>Hum. Gene Ther.</i> 7(17):2079-2087.
	26.	Gao, G. P. et al. (November 1998). "High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus," <i>Hum. Gene Ther.</i> 9:2353-2362.
	27.	Gao, G. P. et al. (December 1996). "Biology of Adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy," <i>J. of Virol.</i> 70(12):8934-8943.
	28.	Gossen, M and Bujard, H. (June 1992). "Tight Control of Gene Expression in Mammalian Cells by Tetracycline-Responsive Promoters," <i>Proc. Natl. Acad. Sci.</i> 89:5547-5551.
	29.	Gossen, M. et al. (June 1995). "Transcriptional Activation by Tetracyclines in Mammalian Cells," <i>Science</i> 268:1766-1769.
	30.	Hansal, S. A. et al. (1998). "Cutting Edge: Induction of Antigen-Specific Hyporesponsiveness by Transplantation of Hemopoietic Cells Containing an MHC Class I Transgene Regulated by a Lymphocyte-Specific Promoter," <i>J. of Immunol.</i> 161:1063-1068.
	31.	Hardy, S. (March 1997). "Construction of Adenovirus Vectors Through Cre-Lox Recombination," <i>J. of Virol.</i> 71(3):1842-1849.
	32.	Harvey, D. M. and Caskey, T. (1998). "Inducible Control of Gene Expression: Prospects for Gene Therapy," <i>Current Opin. in Chem. Biol.</i> 2:512-518.
	33.	Hirt, B. (1967). "Selective Extraction of Polyoma DNA from Infected Mouse Cell Cultures," <i>J. Mol. Biol.</i> 26(2):365-369.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 226272007801

Application Number 10/089,394

Applicant

Haifeng CHEN and Gary KURTZMAN

Filing Date March 29, 2002

Group Art Unit To Be Assigned

Mailing Date May 17, 2002

- | | |
|-----|---|
| 34. | Jones, S. N. and Shenk, T. (January 1978). "Isolation of Deletion and Substitution Mutants of Adenovirus Type 5," <i>Cell</i> 13(1):181-188. |
| 35. | Kyöstiö, S.R. M. et al. (November 1995). "Negative Regulation of the Adeno-Associated Virus (AAV) P ₅ Promoter Involves Both the P ₅ Rep Binding Site and the Consensus ATP-Binding Motif of the AAV Rep68 Protein," <i>J. Virol.</i> 69(11):6787-6796. |
| 36. | Li, J. et al. (July 1997). "Role for Highly Regulated Rep Gene Expression in Adeno-Associated Virus Vector Production," <i>J. of Virol.</i> 71(7):5236-5243. |
| 37. | Li, J. et al. (March 1999). "Synthetic Muscle Promoters: Activities Exceeding Naturally Occurring Regulatory Sequences," <i>Nat. Biotech.</i> 17:241-245. |
| 38. | Macejak, D. G. and Sarnow, P. (September 1991). "Internal Initiation of Translation Mediated by the 5' Leader of a Cellular mRNA," <i>Nature</i> 353: 90-94. |
| 39. | Magari, S. R. et al. (1997). "Pharmacologic Control of a Humanized Gene Therapy System Implanted into Nude Mice," <i>J. Clin. Invest.</i> 100:2865-2872. |
| 40. | Miyatake, S. I. et al. (July 1997). "Transcriptional Targeting of Herpes Simplex Virus for Cell-Specific Replication," <i>J. of Virol.</i> 71:5124-5132. |
| 41. | No, D. et al. (April 1996). "Ecdysone-Inducible Gene Expression in Mammalian Cells and Transgenic Mice," <i>Proc. Natl. Acad. Sci.</i> 93:3346-3351. |
| 42. | Pelletier, J and Sonenberg, N. (July 1988). "Internal Initiation of Translation of Eukaryotic mRNA Directed by A Sequence Derived From Poliovirus RNA," <i>Nature</i> 324:320-325. |
| 43. | Piccioli et al. (July 1991). "Neuroantibodies: Molecular Cloning of a Monoclonal Antibody Against Substance P for Expression in the Central Nervous System," <i>Proc. Natl. Acad. Sci.</i> 88:5611-5615. |
| 44. | Piccioli, P. et al. (August 1995). "Neurantibodies: Ectopic Expression of a Recombinant Anti-Substance P Antibody in the Central Nervous System of Transgenic Mice," <i>Neuron.</i> 15:373-384. |
| 45. | Rivera, V. M. et al. (September 1996). "A Humanized System for Pharmacologic Control of Gene Expression," <i>Nat. Medicine</i> 2(9):1028-1032. |
| 46. | Sandig, V. et al. (1996). "HBV-Derived Promoters Direct Liver-Specific Expression of an Adenovirally Transduced LDL Receptor Gene," <i>Gene Ther.</i> 3:1002-1009. |
| 47. | Stein, G. S. et al. (1997). "The Osteocalcin Gene: A Model for Multiple Parameters of Skeletal-Specific Transcriptional Control," <i>Mol. Biol. Rep.</i> 24:185-196. |
| 48. | Wang, X. S. and Srivastava, A. (June 1998). "Rescue and Autonomous Replication of Adeno-Associated Virus Type 2 Genomes Containing Rep-Binding Site Mutations in the Viral P ₅ Promotor," <i>J. of Virol.</i> 72(6):4811-4818. |
| 49. | Wang, Y. et al. (March 1997). "Ligand-Inducible and Liver-Specific Target Gene Expression in Transgenic Mice," <i>Nat. Biotech.</i> 15:239-243. |
| 50. | Wang, Y. et al. (1997). "Positive and Negative Regulation of Gene Expression in Eukaryotic Cells with an Inducible Transcriptional Regulator," <i>Gene Ther.</i> 4:432-441. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 226272007801

Application Number 10/089,394

Applicant

Haifeng CHEN and Gary KURTZMAN

Filing Date March 29, 2002

Group Art Unit To Be Assigned

Mailing Date May 14, 2002

- | | |
|-----|--|
| 51. | Weitzman, M. D. et al. (March 1996). "Recruitment of Wild-Type and Recombinant Adeno-Associated Virus into Adenovirus Replication Centers," <i>J. of Virol.</i> 70(3):1845-1854. |
| 52. | Xiao, X. et al. (March 1998). "Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus," <i>J. of Virol.</i> 72(3):2224-2232. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.